The synthesis, standardization, and immunogenicity in young outbred mice and clinical evaluation in adult volunteers of investigational vaccines designed to induce serum antibodies to the type 5 and type 8 capsular polysaccharides (CPs) of Staphylococcus aureus are described. Conjugates composed of the type 5 CP and a sonicated preparation of a high-molecular-weight type 8 CP bound to a nontoxic recombinant protein derived from Pseudomonas aeruginosa exotoxin A (rEPA) were synthesized. The conjugates were nontoxic and elicited serum CP antibodies after two subcutaneous injections into young outbred mice; a third injection elicited a booster response. The lower-molecular-weight type 8 CP was not immunogenic in the mice, and the high-molecular-weight type 8 CP elicited low levels of antibodies without a booster effect. In the volunteers, neither the conjugates nor the type 8 CP alone caused significant local reactions or fever. The conjugates elicited type-specific antibodies of both the immunoglobulin M (IgM) and IgG classes after the first injection; a second injection 6 weeks later did not stimulate a booster effect. The high-molecular-weight type 8 CP alone, injected once only, elicited levels of IgG and IgM type-specific antibodies similar to those of the conjugate. The vaccine-induced CP antibodies were mostly of the IgGl and IgG2 subclasses and had opsonophagocytic activity. The conjugates elicited IgG antibodies to the native exotoxin A with neutralizing activity. In summary, the type 5 and type 8 conjugates were safe and elicited biologically active antibodies to both the CP and rEPA components.
Systemic infections due to Staphylococcus aureus are common and serious. Septicemia is ranked 13th as the cause of death in the United States by analysis of death certificates (5) . In most series of severe nosocomial infections, S. aureus was the most common organism causing bacteremia, accounting for approximately one-fourth of the isolates (32, 33, 35) . In addition, many patients suffer from the complications of bacteremia, such as endocarditis, arthritis, and osteomyelitis (18, 44) . S. aureus may be isolated from the skin and nasopharynx of -25% of healthy individuals and is considered to be an opportunistic pathogen because it rarely causes systemic infections in otherwise healthy individuals (6, 47) . Patients with end-stage renal disease undergoing dialysis or after cardiac surgery or who have sustained severe trauma are particularly susceptible to bacteremia caused by S. aureus (1, 30, 39, 57) . S. aureus is a common cause of systemic infection in infants (45, 54) : in some series, this organism was the most common pathogen isolated from infants with systemic infections in developing countries (7) . Recently, outbreaks of bacteremia caused by S. aureus resistant to methicillin have been reported (17, 18, 34) . In one study, a predominance (87%) of methicillin-resistant S. 1024 FAYTOM ET AL. cines of meningococci, pneumococci, and H. influenzae type b (40) . Because conjugates are more immunogenic than polysaccharides alone in both healthy and immunocompromised adults (40, 42, 43, 46, 48) , we developed methods for synthesizing conjugates with the type 5 and 8 CPs of S. aureus, using Pseudomonas aeruginosa exotoxin A (ETA) as the carrier protein (7, (13) (14) (15) . We chose ETA because this protein is unrelated serologically to S. aureus and because there is evidence that antibodies to this ETA confer protection against P. aeruginosa (36, 37) . In young outbred mice, these conjugates were more immunogenic than the CPs alone and elicited type-specific antibodies that facilitated opsonization as well as neutralizing antibodies to the ETA. The conjugation procedure reduced the toxicity of the ETA -1,000-fold but did not eliminate its activity (14) . For this reason, we used the recombinant cross-reacting mutant protein that has glutamic acid 553 and several adjacent residues deleted (3, 6, 23, 31) . This recombinant protein, designated rEPA, has no detectable ADP-ribosyl activity and is indistinguishable antigenically from the native ETA (31) .
In this study, we report the synthesis, safety, and some immunologic properties of conjugates, composed of S. aureus type 5 and 8 CPs covalently bound to P. aeruginosa rEPA, in young outbred mice and in adult volunteers. In addition, we evaluated a high-molecular-weight type 8 CP from a newly discovered strain of S. aureus (23a) .
MATERIALS AND METHODS Bacteria. S. aureus type 5 (strain Lowenstein) and type 8 (strain Wright) were described previously (26) . A mucoid strain of type 8, 013, was isolated from a patient with cystic fibrosis. The rEPA was prepared from a recombinant strain of Eschenchia coli, BL21 (XDE3), transfected with the expression vector pVC45Df+T (6, 11, 23) . A deletion mutant was prepared by oligonucleotide-directed mutagenesis of the cloned P. aeruginosa ETA gene in E. coli. This vector was constructed as described previously (23) , resulting in a recombinant protein with the Glu-553 missing.
Reagents. Pyrogen-free water and pyrogen-free saline (Travenol Laboratories, Deerfield, Ill.) were used throughout these experiments. DNase, RNase, protease, lysostaphin, dithiothreitol (DTT), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide were from Sigma Chemical, St. Louis, Mo. Cystamine and cysteamine were from Fluka, Buchs, Switzerland. Bicinchoninic acid and N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) were from Pierce Chemical Co., Rockford, Ill. Hyperimmune rabbit sera, prepared by multiple intravenous injections of Formalininactivated S. aureus type 5 (strain Lowenstein) or type 8 (strain Wright), have been described (25, 26) .
Polysaccharides. S. aureus type 5 (strain Lowenstein) was used to prepare the CPs for the conjugates and the enzymelinked immunosorbent assay (ELISA). Strain 013 was used to prepare the type 8 CP for the vaccines, and strain Wright was used to prepare the type 8 CP for ELISA. The strains were grown in 100 liters of ultrafiltered Columbia broth (Difco) supplemented with 2% NaCl at 37°C, with -10% 02 saturation, in a 300-liter fermentor for -18 to 22 h. When maximal agglutination of the cells with the homologous antiserum was observed, phenol-ethanol (1:1, vol/vol) was added to a final concentration of 2% and the temperature was brought to 20°C for 6 h. The culture was then centrifuged. We obtained -1 kg of cell paste from each cultivation. The CPs were purified from 500 g of cell paste by enzyme treatment, anion-exchange chromatography, and gel filtration as described previously (14, 19, 33 (12) . To isolate the rEPA from the cells, the culture was centrifuged at 8,000 x g for 15 min (10, 11) . The pellet was suspended in 20% sucrose-20 mM Tris buffer (pH 7.6) (half the original volume) at 4°C. After incubation for 20 min, the cells were pelleted at 10,000 x g at 4°C for 15 min and suspended in cold water in one-third of the original volume. After mixing gently for 10 min, the mixture was centrifuged at 4,000 x g for 15 min. The supernatant, containing the rEPA, was adjusted to 2 mM Tris (pH 7.6), mixed with DEAE-Sepharose equilibrated with the Tris buffer overnight at 3 to 8°C, and packed into a column. The column was washed with 6 column volumes of the Tris buffer, and then a linear gradient of 8 column volumes, 0.0 to 0.5 M NaCl in 20 mM Tris (pH 7.6), was applied. Fractions that contained rEPA, as detected by capillary precipitation with ETA antiserum and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), were pooled and applied to a Mono Q column (Pharmacia, Piscataway, N.J.) (13) . Gradient elution from this column yielded purified rEPA that was concentrated by vacuum dialysis and sterile filtered. The final product showed a distinct band corresponding to rEPA and an identical line of precipitation with ETA by immunodiffusion with ETA antiserum (results not shown). The rEPA had 106 lower specific ADP-ribosyl transferase activity than the native ETA (15, 22) .
Immunization of mice. Female 6-to 8-week-old generalpurpose mice from the NIH colony were injected biweekly subcutaneously with 2.5 ,ug of the CP alone or as a conjugate in 0.1 ml; 10 mice from each group were bled before the second injection and 1 week after the last two injections.
Analyses. The nucleic acid contents of the CPs were measured by their A260 as described previously (55) . Sulfhydryl (SH) groups were measured by the method of Ellman, with cysteine as the standard (15) . Protein was measured and SDS-PAGE was performed as described previously (15) . Gel filtration and calculation of the partition coefficient of the CP and proteins has been described (55) . High-performance liquid chromatography (HPLC) of the conjugates has been described (16 Conjugation. The reduced CP-cystamine derivative was added to a reaction flask and flushed with argon, an equal weight of rEPA-SPDP was added, and the reaction mixture (-3.0 mg of each component per ml) was tumbled under argon for 3 days at 3 to 8°C. The reaction mixture was centrifuged at 10,000 x g at 3 to 8°C for 20 min, and the supernatant was passed through a column of S-300 Sephacryl (5 by 95 cm) in 0.2 M NaCl-0.01% thimerosal. A 0.5-ml aliquot was removed from every third fraction, and its A206 and A280 were recorded. The peak that emerged in the void volume was dispensed in 2.8-ml aliquots into 5.0-ml vials by the Pharmacy Branch, Clinical Center, National Institutes of Health. These vials were assayed for sterility, pyrogenicity, and general safety according to the U.S. Code of Federal Regulations. Two lots of type 5 CP-rEPA (lots 49704 and 50179) and one lot of type 8 CP-rEPA (lot 51008) were used.
Toxicity of rEPA. The rEPAs and the conjugates were assayed in vivo as described previously (22) . General-purpose female mice from the NIH colony, 6 to 8 weeks old, were injected intraperitoneally with 0.5 ml of ETA, rEPA, or the conjugates in the final container, diluted twofold in 0.1% bovine serum albumin (BSA) in PBS. The surviving mice were exsanguinated after 48 h, and the sera were assayed for serum glutamic oxalacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) by Medpath Laboratories, Rockville, Md. The controls were mice injected with 0.1% BSA in PBS.
Toxicity was assayed in vitro with CHO cells grown in RPMI medium supplemented with 5% fetal calf serum for 3 days (14, 22) . The cells were harvested and suspended at 105/ml, and 200-,ul aliquots were added to the wells of a microtiter plate containing serial dilutions of the test samples. The plates were incubated at 37°C in 5% CO2 for 2 days. The wells were emptied, washed, fixed, and stained with Giemsa stain. The end point was the lowest concentration of the sample that killed >95% of the cells.
Vaccines. These vaccines were approved for investigation by the National Institutes of Health (protocol 90 CH 176) and the Food and Drug Administration (protocol BB IND 3679).
Serology. Serum antibodies to the S. aureus type 5 and 8 CPs were measured by ELISA (13, 51) . Biotin-labelled CPs prepared with rEPA that had an SPDP/protein ratio of 6.8, and lot 50179 was prepared with rEPA that had an SPDP/protein ratio of 6.0. In the preparation of lot 49704, the type 5 thiol derivative was concentrated to -5 mg/ml before mixing it with the rEPA-SPDP. The protein/CP ratios in the two type 5 conjugates were similar, but these preparations had different HPLC profiles. Only a small portion of lot 49704 eluted in the void volume, and the major peak eluted at 7.5 min. A higher proportion of lot 50179 than lot 49704 eluted in the void volume, and the major peak eluted at 6.5 min. The type 8 CP-rEPA conjugate, lot 51008, used a CP with a similar degree of thiolation (5.7% SH) but with a larger molecular size than that of the type 5 CP. The high-molecular-weight type 8 CP, lot 51708, eluted in the void volume of a CL-2B Sepharose column.
Toxicity of rEPA and the conjugates (Table 2 ). Similar to published data (14, 22) , the 50% lethal dose (LD50) of the ETA was -0.2 ,ug per mouse. Mice injected with 0.1 p.g of ETA looked sick, lost weight compared with other groups, and had significant elevations of SGOT and SGPT levels (P < 0.05). No detectable change in the appearance of mice injected with 0.05 ,ug of ETA was noticed, but this dose elicited a rise in SGOT and SGPT levels (P < 0.006 versus 0.1% BSA in PBS). Neither lot of rEPA at 200 or 400 ,g per mouse nor any of the vaccines at -25 ,ug of rEPA per mouse caused death or a rise in the level of SGOT or SGPT. The levels of SGOT and SGPT in the mice that received -25 ,ug of rEPA each were similar to those observed in mice injected with 0.1% BSA in PBS.
Immunization of mice ( Table 3 ). The type 5 CP alone did not elicit antibodies in the mice. The type 8 CP alone elicited low levels of antibodies after the first injection (not significant), which rose slightly after both the second and third injections (not significant). The two type S and the type 8 conjugates did not elicit CP antibodies after the first injection. All three conjugates elicited significant rises of typespecific antibodies after the second and third injections (P < 0.02). Type 5 CP-rEPA lot 50179 elicited higher levels of CP antibodies than lot 49704 after both the second (P = 0.01) and third (P = 0.01) injections. The type 8 CP-rEPA, lot 51008, elicited higher levels of antibodies than the type 8 CP alone after the second and third injections (P = 0.0001 for the third injection). As expected, type 5 CP-rEPA lot 50179 did not elicit a rise of type 8 CP antibodies. Table 5 ). The preimmunization levels of IgM and IgG type 5 CP antibodies were similar in both groups of volunteers. Two weeks after the first injection, both conjugates elicited significant rises in the geometric mean IgG and IgM levels in all of the recipients (P < 0.0001): all responded with a >4-fold rise in type 5 IgG antibodies. Six weeks after the first immunization, volunteers immunized with lots 49704 and 50179 had 33-and 37-fold rises of their type 5 CP IgG antibody levels and 15-and 10-fold rises of their IgM CP antibodies, respectively. A second injection of either of the type 5 conjugates did not elicit a rise of CP antibodies. About 6 months later, the levels of type 5 antibodies declined slightly: IgG levels decreased 26% (lot 49704) and 14% (lot 50179), and IgM antibodies decreased about 50% in both groups. Lot 50179 elicited higher levels of IgG type 5 antibodies after the first immunization, and, 26 weeks later, these levels remained about twofold higher than those of the volunteers injected with lot 49704 (274 ,ug of antibody per ml versus 166 ,ug of antibody per ml, P < 0.05); the IgM antibody levels were similar for both groups.
Type 8 CP antibodies (Table 6 ). Preimmunization levels of type 8 antibodies in both groups were similar. Immunization with the type 8 CP-rEPA (lot 51008) or with the type 8 CP alone (lot 51708) elicited about an eightfold increase of IgG antibodies and about a fivefold increase of IgM antibodies (both, P = 0.0001). These levels were observed 2 and 6 weeks after the first immunization and did not change after the second immunization or at the 6-month check-up. The type 8 CP conjugate (lot 51008) elicited higher levels of IgM antibodies than lot 51708 at all times, but these differences were not significant.
IgG subclass composition of CP antibodies ( Table 7 ). The IgG subclasses of CP antibodies from the preimmunization and 6-week postimmunization sera were assayed. All volunteers responded with significant rises of IgGl or IgG2 antibodies (P < 0.01); most responded with significant rises in both subclasses. Opsonophagocytic activity of vaccine-induced CP antibodies (Fig. 1) . As reported, preimmunization sera from rabbits and the volunteers induced no or a slight (-1/2 log) reduction in the number of S. aureus bacteria of type 5 or 8 after incubation with human peripheral blood mononuclear leukocytes (14, 25) . The hyperimmune rabbit serum and the postimmunization sera of the volunteers elicited a typespecific reduction in the number of S. aureus bacteria of from 1.5 to 4 logs. Not shown was the failure of CP-adsorbed sera to elicit this bactericidal effect.
Anti-ETA antibodies (Table 8) . Most of the volunteers had nondetectable or low levels of ETA antibodies in their preimmune sera. Immunization with the type 5 CP-rEPA conjugates elicited an increase in the geometric mean ETA antibody levels (P = 0.0001), and the levels in the two groups (14), the first injection of the S. aureus type 5 or 8 rEPA conjugates did not elicit CP antibodies in mice. Since the compositions and molecular sizes of these conjugates were similar, we suggest that the residual activity of the ETA exerted an adjuvant effect upon CP antibody synthesis over that of the rEPA. The three conjugates elicited CP antibodies in the mice after the second injection and a booster response after the third injection; the high-molecular-weight type 8 CP (lot 51708) elicited low levels of antibodies after the first injection, which did not change after the second and third injections. The lower-molecular-weight type 5 and 8 CPs in our previous work (14, 15) and the type 5 CP in this study did not elicit antibodies in the mice. We conclude that covalent binding to the rEPA both increased the immunogenicity and conferred T-cell-dependent properties upon the type 5 and 8 CPs. In addition, type 5-rEPA lot 50179 elicited higher levels of CP antibodies in the mice than lot 49704, which correlated with their molecular sizes by HPLC and was predictive of their immunogenicity in the volunteers. The only difference in the synthesis of these conjugates was the higher concentration of the type 5 CP-SH derivative used for the conjugation reaction of lot 49704 than of lot 50179. This difference may have resulted in the lower molecular weight of type 5 CP-rEPA lot 49704 compared with lot 50179. We have no explanation for this finding, but it does give us information about the requirements for future lots of S. aureus CP conjugates. Similarly, we found a greater immunogenicity of Vi protein conjugates of higher molecular weight prepared by different synthetic schemes (15, 52) .
Unlike the sera of the mice, the preimmunization sera of the volunteers had low levels of both IgM and IgG antibodies to the type 5 and 8 CPs. The presence of these "natural" antibodies could be due to carriage of the homologous organisms and/or bacteria with cross-reacting antigens, as has been observed in the sera of adult humans and animals with other CPs (28, 40, 41) . The presence of these natural antibodies could explain the failure of our conjugate vaccines to elicit a booster response to either of the two CPs in the volunteers; the initial response is likely a booster in a sensitized host (13, (40) (41) (42) (43) . The failure to elicit a booster response in adults has been observed with other capsular and 0-specific polysaccharide conjugate vaccines (9, 13, 40) . In patients with AIDS, conjugates of H. influenzae type b CP elicited a lesser response than they did in healthy controls: the effect of reinjection of these vaccines in patients with AIDS was not reported (48 (31) . This lesser immunogenicity in mice could be due to the elimination of biological activity or a reduction in the immunogenicity of the native toxin by the genetically induced mutation. It has been reported that ETA has adjuvant-like properties in mice (27) . The rEPA has no residual activity and, therefore, would not be expected to exert a modulating effect upon the immunologic properties of the conjugate. The immunogenicity of the S. aureus CPs was enhanced after their covalent binding to the rEPA. These conjugates elicited no or minor side effects in all 70 volunteers. We plan to compare the levels of antibodies induced by these conjugates in patients at increased risk for bacteremia caused by S. aureus.
